Prevalence and Impact of Preexisting Comorbidities on Overall Clinical Outcomes of Hospitalized COVID-19 Patients

Table 5

Severity of disease in hospitalized COVID-19 patients.

Variable	Total (, %)	Mild (, % within total)	Moderate (, % within total)	Severe (, % within total)
No morbidity	151	86 (57.0)	32 (21.2)	33^a (21.9)
DM	44	10 (22.7)	16 (36.4)	18^b (40.9)
HTN	30	9 (30.0)	7 (23.3)	14^a (46.7)
CAD	7	0 (0.0)	4 (57.1)	3^a (42.9)
CKD	3	0 (0.0)	0 (0.0)	3^b (100.0)
	67	11 (16.4)	21 (31.3)	35^b (52.2)
	29	3 (10.3)	11 (37.9)	15^b (51.7)
	11	0 (0.0)	3 (27.3)	8^b (72.7)
	11	0 (0.0)	2 (18.2)	9^b (81.8)
	4	1 (25.0)	0 (0.0)	3^b (75.0)
	9	2 (22.2)	4 (44.4)	3^a (33.3)
value				≤0.001

Notes: suggests significant association between comorbidity groups and severity of the disease. -test was viewed for comparison of proportions between no comorbidity and other comorbidity groups. Variations in superscripts (a, b) indicate significance () of disease severity across these groups.